Phase 2
N=24
Evaluating the Impact of JJVC Senofilcon A - Based Contact Lens With New UV-blocker on Day and Night Driving Performance
Visual Performance
Bottom Line
View on ClinicalTrials.gov: NCT03330275 ↗Enrolled (actual)
24
Serious AEs
0.0%
Results posted
Aug 2018
Primary outcome: Primary: Overall Nighttime Driving Score — -0.308; -0.375; -0.430 Z-Score
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Investigational Contact Lens (Device); Commercial ACUVUE OASYS (Device); Commercial ACUVUE OASYS and Spectacles (Device)
- Age
- Adult · 20+ yrs
- Sex
- All
- Sponsor
- Johnson & Johnson Vision Care, Inc.
- Primary completion
- Dec 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Overall Nighttime Driving Score |
-0.308; -0.375; -0.430 | — |
| SECONDARY Binocular Visual Acuity |
0.251; 0.273; 0.298 | — |
| SECONDARY Binocular Contrast Threshold Without Glare |
100; 100; 100; 100; 95.8; 95.8 | — |
| SECONDARY Percentage of Road Signs Correctly Identified During Night Driving |
72.7; 73.3; 73.3 | — |
| SECONDARY Average Distance to Correctly Identify Road Signs During Night Driving |
110.3; 101.5; 95.0 | — |
| SECONDARY Percentage of Hazards Avoided During Night Driving |
95.4; 95.4; 93.1 | — |
| SECONDARY Average Pedestrian Recognition Distance |
208.3; 201.1; 195.5 | — |
Summary
This is a bilateral, non-dispensing, randomized, subject masked, four visits, 3-period by 3- treatment crossover study. The objective of this study is to evaluate the effect of JJVC senofilcon A - based contact lens with new UV-blocker on vision and driving performance in both daytime and nighttime lighting under real world driving conditions. This will be achieved through field-based driving studies on a closed-road driving circuit at night and during the day. Quantitative methods will be used to assess vision and driving performance under a range of challenging conditions and appropriate masking, order of testing, randomization and control conditions will be used.
Eligibility Criteria
Inclusion Criteria
- Potential subjects must satisfy all of the following criteria to be enrolled in the study:
- The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
- Appear able and willing to adhere to the instructions set forth in this clinical protocol.
- Between 20 and 49 (inclusive) years of age at the time of screening.
- Presbyopic subjects must be habitual wearers of distance vision correction in both eyes.
- The subject's vertex corrected spherical equivalent distance refraction must be in the range of -1.00 through -6.00 D (inclusive) in each eye.
- The subject's refractive cylinder must be ≤ 1.00 D in each eye.
- Have spherocylindrical best corrected visual acuity of 20/20 or better in each eye.
- Be a current soft contact lens wearer in both eyes, defined as at least 5 days per week and 6 hours per day averaged over the past 30 days.
- Hold a current Open driver's license
- Be a regular driver (at least once per week)
- Have at least one year of driving experience
Exclusion Criteria
- Potential subjects who meet any of the following criteria will be excluded from participating in the study:
- Currently pregnant or lactating
- Any systemic disease (e.g., Sjögren's Syndrome), allergies, infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive diseases (e.g., HIV), autoimmune disease (e.g. rheumatoid arthritis), or other diseases, by self-report, which are known to interfere with contact lens wear and/or participation in the study.
- Use of systemic medications (e.g., chronic steroid use) that are known to interfere with contact lens wear, pupil size or accommodation.
- Any ocular allergies, infections or other ocular abnormalities that are known to interfere with contact lens wear and/or participation in the study. This may include, but not be limited to entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or corneal distortion.
- History of binocular vision abnormality or strabismus
- Any current use of ocular medication
- Any previous, or planned (during the course of the study) ocular surgery (e.g., radial keratotomy, PRK, LASIK, etc.)
- Any grade 3 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA slit lamp biomicroscopy scale
- Any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any other ocular abnormality that would contraindicate contact lens wear
- Employee of clinical site (e.g., Investigator, Coordinator, Technician)
Data sourced from ClinicalTrials.gov (NCT03330275). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.